Pathogenic variants in BRCA1 or BRCA2, or an HRD signature, are associated with favorable outcome of platinum therapy in other cancers such as ovarian cancer,49, 50, 51, 52 triple‐negative BC,53 pancreatic cancer,54 or lung cancer.55 Here, BRCA1 is linked to ovarian carcinoma.